144 related articles for article (PubMed ID: 36216762)
1. A systematic review and meta-analysis of CK20, CD44, Ki67 and p53 as immunohistochemical markers in bladder carcinoma in situ.
Straccia P; Fiorentino V; Martini M; Pierconti F
Actas Urol Esp (Engl Ed); 2022 Nov; 46(9):521-530. PubMed ID: 36216762
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical staining patterns of Ki-67 and p53 in florid reactive urothelial atypia and urothelial carcinoma in situ demonstrate significant overlap.
Nguyen JK; Przybycin CG; McKenney JK; Magi-Galluzzi C
Hum Pathol; 2020 Apr; 98():81-88. PubMed ID: 32142835
[TBL] [Abstract][Full Text] [Related]
3. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens.
McKenney JK; Desai S; Cohen C; Amin MB
Am J Surg Pathol; 2001 Aug; 25(8):1074-8. PubMed ID: 11474293
[TBL] [Abstract][Full Text] [Related]
4. Enhancing upper tract urothelial carcinoma diagnosis: Utility of cytokeratin 17 and CK20/CD44/p53 immunohistochemical panel.
Irwin T; Donlan AW; Owens L; Alvarez R; Vakar-Lopez F; Tretiakova M
Hum Pathol; 2024 Apr; 146():43-48. PubMed ID: 38593961
[TBL] [Abstract][Full Text] [Related]
5. Could double stain for p53/CK20 be a useful diagnostic tool for the appropriate classification of flat urothelial lesions?
Di Sciascio L; Ambrosi F; Franceschini T; Giunchi F; Franchini E; Massari F; Bianchi FM; Colecchia M; Fiorentino M; Ricci C
Pathol Res Pract; 2022 Jun; 234():153937. PubMed ID: 35561522
[TBL] [Abstract][Full Text] [Related]
6. The role of immunohistochemistry in the diagnosis of flat urothelial lesions: a study using CK20, CK5/6, P53, Cd138, and Her2/Neu.
Jung S; Wu C; Eslami Z; Tanguay S; Aprikian A; Kassouf W; Brimo F
Ann Diagn Pathol; 2014 Feb; 18(1):27-32. PubMed ID: 24321464
[TBL] [Abstract][Full Text] [Related]
7. Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia.
Aron M; Luthringer DJ; McKenney JK; Hansel DE; Westfall DE; Parakh R; Mohanty SK; Balzer B; Amin MB
Am J Surg Pathol; 2013 Dec; 37(12):1815-23. PubMed ID: 24225842
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia.
Mallofré C; Castillo M; Morente V; Solé M
Mod Pathol; 2003 Mar; 16(3):187-91. PubMed ID: 12640096
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Roles of Immunohistochemical Markers CK20, CD44, AMACR, and p53 in Urothelial Carcinoma In Situ.
Yoo D; Min KW; Pyo JS; Kim NY
Medicina (Kaunas); 2023 Sep; 59(9):. PubMed ID: 37763728
[No Abstract] [Full Text] [Related]
10. Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases.
Oliva E; Pinheiro NF; Heney NM; Kaufman DS; Shipley WU; Gurski C; Spicer B; Paner GP; Gown AM; Amin MB
Hum Pathol; 2013 May; 44(5):860-6. PubMed ID: 23199526
[TBL] [Abstract][Full Text] [Related]
11. Differential diagnosis of urothelial carcinoma in situ from non-neoplastic urothelia: Analysis of CK20, CD44, P53 and Ki67.
Asgari M; Nabi Maybodi M; Abolhasani M
Med J Islam Repub Iran; 2016; 30():400. PubMed ID: 27579290
[TBL] [Abstract][Full Text] [Related]
12. CK20 and p53 Immunohistochemical Staining Patterns in Urinary Bladder Specimens With Equivocal Atypia.
Arias-Stella JA; Shah AB; Gupta NS; Williamson SR
Arch Pathol Lab Med; 2018 Jan; 142(1):64-69. PubMed ID: 28967804
[TBL] [Abstract][Full Text] [Related]
13. [A useful panel in proliferative urothelial lesions: an analysis of cytokeratin 20, p53, CD44 and Ki-67 antigens].
Russo S; Botti G; Vinaccia P; Iaccarino C; Maioli S; Del Prete D; Maiello FM
Pathologica; 2007 Apr; 99(2):46-9. PubMed ID: 17633807
[TBL] [Abstract][Full Text] [Related]
14. Cytokeratin 20 and Ki-67 to distinguish carcinoma in situ from flat non-neoplastic urothelium.
Yin H; He Q; Li T; Leong AS
Appl Immunohistochem Mol Morphol; 2006 Sep; 14(3):260-5. PubMed ID: 16932015
[TBL] [Abstract][Full Text] [Related]
15. Urothelial carcinoma in situ with "overriding" features can evade detection by mimicking umbrella cells.
Bahceci D; Nguyen JK; Sangoi AR; Stohr BA; Chan E
Hum Pathol; 2023 Jun; 136():56-62. PubMed ID: 36997033
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis of urothelial carcinoma in situ using blue light cystoscopy and the utility of immunohistochemistry in blue light-positive lesions diagnosed as atypical.
Pederzoli F; Murati Amador B; Samarska I; Lombardo KA; Kates M; Bivalacqua TJ; Matoso A
Hum Pathol; 2019 Aug; 90():1-7. PubMed ID: 31071342
[TBL] [Abstract][Full Text] [Related]
17. Atypia in inverted urothelial papillomas: pathology and prognostic significance.
Broussard JN; Tan PH; Epstein JI
Hum Pathol; 2004 Dec; 35(12):1499-504. PubMed ID: 15619209
[TBL] [Abstract][Full Text] [Related]
18. Superficial papillary urothelial neoplasms of the bladder (PTA E PT1): correlation of expression of P53, KI-67 and CK20 with histologic grade, recurrence and tumor progression.
Ogata DC; Marcondes CA; Tuon FF; Busato WF; Cavalli G; Czeczko LE
Rev Col Bras Cir; 2012; 39(5):394-400. PubMed ID: 23174791
[TBL] [Abstract][Full Text] [Related]
19. CK20 versus AMACR and p53 immunostains in evaluation of Urothelial Carcinoma in Situ and Reactive Atypia.
Neal DJ; Amin MB; Smith SC
Diagn Pathol; 2020 May; 15(1):61. PubMed ID: 32456709
[TBL] [Abstract][Full Text] [Related]
20. [Urothelial hyperplastic lesion with endophytic growth pattern: a clinicopathologic study].
Xiao L; Wang CF; Zhu XZ; Yin YL; Chen Y; Lu C; Yu B
Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):319-23. PubMed ID: 21756826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
